JP2024020417A5 - - Google Patents

Download PDF

Info

Publication number
JP2024020417A5
JP2024020417A5 JP2023194557A JP2023194557A JP2024020417A5 JP 2024020417 A5 JP2024020417 A5 JP 2024020417A5 JP 2023194557 A JP2023194557 A JP 2023194557A JP 2023194557 A JP2023194557 A JP 2023194557A JP 2024020417 A5 JP2024020417 A5 JP 2024020417A5
Authority
JP
Japan
Prior art keywords
formulation
particles
lung disease
interstitial lung
ylmethylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023194557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024020417A (ja
Filing date
Publication date
Priority claimed from GBGB2006079.4A external-priority patent/GB202006079D0/en
Application filed filed Critical
Publication of JP2024020417A publication Critical patent/JP2024020417A/ja
Publication of JP2024020417A5 publication Critical patent/JP2024020417A5/ja
Priority to JP2026058471A priority Critical patent/JP2026099828A/ja
Pending legal-status Critical Current

Links

JP2023194557A 2020-04-24 2023-11-15 経口投与用の新しい乾燥粉末組成物 Pending JP2024020417A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026058471A JP2026099828A (ja) 2020-04-24 2026-03-31 経口投与用の新しい乾燥粉末組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2006079.4A GB202006079D0 (en) 2020-04-24 2020-04-24 New composition
GB2006079.4 2020-04-24
JP2022540540A JP7387903B2 (ja) 2020-04-24 2021-04-23 経口投与用の新しい乾燥粉末組成物
PCT/GB2021/050994 WO2021214488A1 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022540540A Division JP7387903B2 (ja) 2020-04-24 2021-04-23 経口投与用の新しい乾燥粉末組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026058471A Division JP2026099828A (ja) 2020-04-24 2026-03-31 経口投与用の新しい乾燥粉末組成物

Publications (2)

Publication Number Publication Date
JP2024020417A JP2024020417A (ja) 2024-02-14
JP2024020417A5 true JP2024020417A5 (cg-RX-API-DMAC7.html) 2024-05-01

Family

ID=71080269

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022540540A Active JP7387903B2 (ja) 2020-04-24 2021-04-23 経口投与用の新しい乾燥粉末組成物
JP2023194557A Pending JP2024020417A (ja) 2020-04-24 2023-11-15 経口投与用の新しい乾燥粉末組成物
JP2026058471A Pending JP2026099828A (ja) 2020-04-24 2026-03-31 経口投与用の新しい乾燥粉末組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022540540A Active JP7387903B2 (ja) 2020-04-24 2021-04-23 経口投与用の新しい乾燥粉末組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026058471A Pending JP2026099828A (ja) 2020-04-24 2026-03-31 経口投与用の新しい乾燥粉末組成物

Country Status (19)

Country Link
US (2) US11844868B2 (cg-RX-API-DMAC7.html)
EP (2) EP4138790B1 (cg-RX-API-DMAC7.html)
JP (3) JP7387903B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005220A (cg-RX-API-DMAC7.html)
CN (1) CN115697309A (cg-RX-API-DMAC7.html)
AU (2) AU2021260923B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022021511A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180646A1 (cg-RX-API-DMAC7.html)
DK (1) DK4138790T3 (cg-RX-API-DMAC7.html)
ES (1) ES2976885T3 (cg-RX-API-DMAC7.html)
GB (1) GB202006079D0 (cg-RX-API-DMAC7.html)
IL (1) IL297373B2 (cg-RX-API-DMAC7.html)
LT (1) LT4138790T (cg-RX-API-DMAC7.html)
MX (1) MX2022013070A (cg-RX-API-DMAC7.html)
PL (1) PL4138790T3 (cg-RX-API-DMAC7.html)
PT (1) PT4138790T (cg-RX-API-DMAC7.html)
SI (1) SI4138790T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021214488A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211460B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
KR20240148359A (ko) 2022-02-10 2024-10-11 바이코어 파마 아베 특발성 폐섬유증 치료를 위한 불록시부티드의 용도
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
WO2005123072A1 (en) 2004-06-14 2005-12-29 Sepracor Inc. Methods and compositions for the treatment of pulmonary diseases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2091539A1 (en) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
CA2821985C (en) * 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
HK1244232A1 (zh) 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
US11931341B2 (en) * 2018-03-22 2024-03-19 University Of Lowa Research Foundation Compositions and methods for the treatment and prevention of muscular dystrophy
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Similar Documents

Publication Publication Date Title
KR101554374B1 (ko) 구강 붕해정
ES2311500T3 (es) Particulas farmaceuticas de sabor enmascarado.
JP5808670B2 (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
AU728526B2 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
ES2274625T3 (es) Comprimidos desintegrables en la boca que comprenden un bencimidazol.
ES2351612T3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer.
TWI686215B (zh) 祛鐵斯若(deferasirox)之口服配方
TWI750143B (zh) 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物
DK158540B (da) Orale, ikke-retarderede dipyridamolformer og fremgangsmaade til deres fremstilling
US20040166162A1 (en) Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP7336388B2 (ja) 錠剤及びその製造方法
JPS601128A (ja) 作用持続型セフアクロル製剤
KR20140007364A (ko) 구강내 붕괴정
JP2010524926A (ja) ウルソデオキシコール酸の高用量組成物
JP2020196713A (ja) エドキサバンを含有する口腔内崩壊錠
BR112020008940A2 (pt) preparação de liberação controlada
ES2197087T3 (es) Tabletas tragables con alto contenido de n-acetilcisteina.
JP2005139085A (ja) 顆粒
JP6366794B2 (ja) 原薬の化学的安定性や服用感を向上した、口腔内崩壊錠
ES2604307T3 (es) Comprimido de disgregación oral revestido por vía seca
ES3050159T3 (en) High dose tranexamic acid composition and process for preparation thereof
WO2019098327A1 (ja) 速溶性薬物の苦味が抑制された口腔内崩壊錠
CN103735551B (zh) 心脑血管的药物组合物及其制备方法和应用
CN103126994B (zh) 含决奈达隆的固体药物组合物
WO2025046633A1 (en) Extended-release formulations for cilnidipine and their manufacturing processes